Australian Prescriber

Best-practice management of behaviours of concern in people with cognitive disability or impairment, with a focus on appropriate use of psychotropic medicines.

An overview of drugs used to manage adults with attention deficit hyperactivity disorder (ADHD), including psychostimulants and non-psychostimulants.

A summary of guideline recommendations regarding intra-articular hyaluronic acid injections for symptomatic osteoarthritis of the knee and other joints, and the evidence that shows conclusively that it is not an effective therapy.

Patients receiving immunosuppressive therapy are at increased risk of infection. This article outlines practical strategies to reduce infection risk, including risk assessment, targeted screening investigations, antimicrobial prophylaxis, vaccination and patient education.

A new Australian guideline for diagnosing and managing acute coronary syndromes was launched in 2025. This article describes key recommendations from the secondary prevention section of the guideline, with a focus on pharmacotherapies.

Ivosidenib is a first-in-class, oral, potent, targeted small-molecule inhibitor of mutant IDH1 with clinical activity in cholangiocarcinoma and acute myeloid leukaemia.

Vutrisiran is a small RNA-interfering agent that reduces amyloid deposition by reducing production of transthyretin, the abnormal protein in hereditary transthyretin amyloidosis.